Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06512389 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

Name: Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder — clinical trial record (NCT06512389)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorCentre for Addiction and Mental Health

Started2024-08-16

View on ClinicalTrials.gov ↗

Amendment history

2026-09-17

Enrollment closed, study ongoing

Primary completion confirmed: August 2026 (last estimated June 2026)

Completion pushed: 2026-06-30 → 2026-09-30

2026-03-19

Study Status v2

Primary completion date2026-12-31→2026-06-30

Completion date2026-12-31→2026-06-30

2024-08-22

Study Status, Outcome Measures v1

Start dateestimated 2024-07-31→confirmed 2024-08-16

Secondary endpointsdetails revised at 2 of 6 entries

2024-07-16

Original filing

Centre for Addiction and Mental Health

106 trials monitored

See 10 trials at risk

This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2-week washout period separating the two treatment phases.

Trial Details

NCT Number	NCT06512389
Lead Sponsor	Centre for Addiction and Mental Health
Conditions	Alcohol Use Disorder
Enrollment	36 participants
Start Date	2024-08-16
Primary Completion	2026-08-20 (estimated)
Study Completion	2026-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-16